Reviving therapies With Untapped Potential

Contact

Mission

Many promising therapies never reach patients-not because they failed, but because funding disappeared, priorities shifted, acquisitions occurred or new leadership took a different direction.

Resurgent Therapeutics Advisory exists to identify those opportunities & help organizations build practical, efficient, evidence-based paths towards clinical development & ultimately commercial success.

Services

  • Strategic Asset Assessment

    Independent evaluation of therapeutic assets, development plans & risks, competitive positioning & value creation opportunities

  • Clinical Development Planning

    Design efficient development pathways including Pre-IND & Phase I-III planning, indication prioritization, protocol strategy & operational guidance

  • Due Diligence

    Scientific & clinical diligence and deep data review for investors, licensors & acquisition teams evaluating therapeutic programs

  • Fractional Chief Development Officer

    Executive leadership for emerging biotechnology companies that need experienced strategic support without hiring a full-time executive

Who We Work With

  • Emerging Biotech

  • Pharma BD teams

  • Venture Capital

  • Private Equity

  • Academic Spinouts

  • Family Offices

About

Michael Mandola, Ph.D. - Founder & Principal Consultant

Mike Mandola, PhD, is a biopharmaceutical executive with more than 20 years of oncology experience spanning program leadership, clinical development, business development, global corporate partnerships & medical strategy. He most recently served as Senior Vice President, Head of Program Strategy & Leadership at Merck Healthcare, following progressive leadership roles at Bristol Myers Squibb.

Currently he serves as a Scientific Advisory Board member in biotech & Strategic Innovation Board member for The Max Foundation, a non-profit focused on providing life-saving cancer medications to low- and middle- income countries.

During his tenure in pharma, Mike worked across oncology programs spanning pre-IND to post-marketing. Mike has led numerous due diligence exercises, including taking the helm as Program Leader for successful partnerships.

Mike holds a PhD in Molecular Biology from the University of Medicine and Dentistry of NJ (now Rowan University) and a BS in Biology from Stockton University. He conducted his post-doctoral research at the Fox Chase Cancer Center and The Cancer Institute of NJ.